Novartis Ag (NVS) Net Margin Growth (3y) (2012 - 2026)
Novartis Ag (NVS) Net Margin Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | -204.00 |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 666.00 |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 3,167.00 |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | -43,067.00 |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 37.00 |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 388.00 |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | -15,026.00 |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -6,857.00 |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -1,745.00 |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | -1,144.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -43,067.00 |
| Jun 30, 2025 | -19,359.00 |
| Dec 31, 2024 | -8,575.00 |
| Jun 30, 2024 | -8,358.00 |
| Dec 31, 2023 | -2,964.00 |
| Sep 30, 2023 | -756.34 Mn |
| Jun 30, 2023 | -2,091.00 |
| Mar 31, 2023 | -3,673.00 |
| Dec 31, 2022 | -2.74 Mn |
| Sep 30, 2022 | -157,656.00 |
| Jun 30, 2022 | 5,519.00 |
| Mar 31, 2022 | 1.32 Bn |
| Dec 31, 2021 | -3.42 Mn |
| Sep 30, 2021 | -427,070.00 |
| Jun 30, 2021 | -25,913.00 |
| Mar 31, 2021 | 498.27 Mn |
| Dec 31, 2020 | 3,950.00 |
| Sep 30, 2020 | 756.36 Mn |
| Jun 30, 2020 | 45,807.00 |
| Mar 31, 2020 | -75,794.00 |